COVID-19 and cellular therapy


References in bold are published by MATHEC members

2022
Mesenchymal stem cell treatment for COVID-19
Xu R, Feng Z,and Wang F-S
EBioMedicine. 2022 Mar;77:103920.doi: 10.1016/j.ebiom.2022.103920. Epub 2022 Mar 10.

Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications
Chen L, Qu J, Kalyani FS, Zhang Q, Fan L, Fang Y, Li Y, Xiang C
Cell Mol Life Sci. 2022 Feb 20;79(3):142.doi: 10.1007/s00018-021-04096-y.

COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease
Alsuliman T, Stocker N, Van de Wyngaert Z, Ikhlef S,Ellouz C,Corre E,Banet A, Ricard L,Dulery R,Meynard JL,Malard F, Stankoff B,Farge-Bancel D,Brissot E,Mohty M,Marjanovic Z.

2021

Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations
Greco R, Alexander T, Burman J, Del Papa N, de Vries-Bouwstra J, Farge D, Henes J, Kazmi M, Kirgizov K, Muraro P A, Ricart E, Rovira M, Saccardi R, Sharrack B, Snarski E, Withers B, Jessop H, Boglione C, Kramer E, Badoglio M, Labopin M, Orchard K, Corbacioglu S, Ljungman P, Mikulska M, De la Camara R, Snowden J A, European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP), Infectious Diseases Working Party (IDWP), Pediatric Working Party (PWP), Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE), EBMT Nurses Group and Patient Advocacy Committee
Bone Marrow Transplant. 2021 Jul;56(7):1493-1508.doi: 10.1038/s41409-021-01326-6. Epub 2021 May 24.